Trilostane
- Generic Name
- Trilostane
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27NO3
- CAS Number
- 13647-35-3
- Unique Ingredient Identifier
- L0FPV48Q5R
- Background
Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.
- Indication
用于治疗皮质醇增多症（库欣综合征），也可用于醛固酮增多症和高雄激素血症。
- Associated Conditions
- -
- Associated Therapies
- -
Randomized Study of Letrozole and Trilostane for Medical Abortion
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Kristina Gemzell Danielsson
- Target Recruit Count
- 36
- Registration Number
- NCT01615211
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
Trilostane for Androgen-Independent Prostate Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 24
- Registration Number
- NCT00181597
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath